生命科学资讯
生物技术与制药领域的最新动态
CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
研发百强获奖者聚焦：深入解读赛默飞世尔科技2025年三项研发百强奖项——研发世界
R&D 100 Winner Spotlight: A closer look at Thermo Fisher Scientific's trio of R&D 100 wins in 2025 - R&D World
赛默飞世尔科技2025年第四季度财报前瞻：近期内部交易、对冲基金活动及其他动态——Quiver Quantitative
THERMO FISHER SCIENTIFIC Q4 2025 Earnings Preview: Recent $TMO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Breaking Down 10x Genomics: 13 Analysts Share Their Views - Benzinga
Hospitals could earn more for buying US-made drugs, CMS proposes
心脏病发作新解：神经系统紊乱或成新药靶点
Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets
TD Cowen精选其“骨骼、机器人与无针注射”投资组合中的三大医疗科技潜力股。
TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio
卡迪夫高管离职，公司二期试验数据喜忧参半。
Cardiff execs depart as company drops mixed Phase 2 data
联合健康集团调整业务布局，预计2026年营收将下滑
UnitedHealth projects lower revenue in 2026 as it resets its business
Former Cytodyn CEO faces prison time, millions in restitution
2026年1月27日任命与晋升公告
Appointments and advancements for Jan. 27, 2026
2026年1月27日融资动态
Financings for Jan. 27, 2026
2026年1月27日门诊
In the clinic for Jan. 27, 2026
2026年1月27日其他值得关注的消息
Other news to note for Jan. 27, 2026
2026年1月27日监管动态
Regulatory actions for Jan. 27, 2026
FDA解除对Intellia CRISPR药物试验的暂停。
FDA lifts hold on an Intellia CRISPR drug trial
罗氏在肥胖症领域落后，展示GLP-1注射剂新数据
Roche, trailing in obesity, showcases new data for GLP-1 shot
AI原生门诊手术初创公司Oath Surgical与英伟达达成合作
'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership